These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 20008760)

  • 21. Cost-effectiveness of influenza vaccination in working-age cancer patients.
    Avritscher EB; Cooksley CD; Geraci JM; Bekele BN; Cantor SB; Rolston KV; Elting LS
    Cancer; 2007 Jun; 109(11):2357-64. PubMed ID: 17457827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of introducing an MF59-adjuvanted trivalent influenza vaccine for older adults in Argentina.
    Nguyen VH; Vizzotti C; Uruena A; Giglio N; Magneres C; Richmond H
    Vaccine; 2020 Apr; 38(20):3682-3689. PubMed ID: 32249017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older.
    Smith KJ; Zimmerman RK; Nowalk MP; Lin CJ
    J Am Geriatr Soc; 2017 Apr; 65(4):763-768. PubMed ID: 28024090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medical countermeasures for pandemic influenza: ethics and the law.
    Gostin LO
    JAMA; 2006 Feb; 295(5):554-6. PubMed ID: 16449621
    [No Abstract]   [Full Text] [Related]  

  • 25. Vaccination strategies for future influenza pandemics: a severity-based cost effectiveness analysis.
    Kelso JK; Halder N; Milne GJ
    BMC Infect Dis; 2013 Feb; 13():81. PubMed ID: 23398722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States.
    Clements KM; Chancellor J; Nichol K; DeLong K; Thompson D
    Value Health; 2011; 14(6):800-11. PubMed ID: 21914499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
    Aballéa S; Chancellor J; Martin M; Wutzler P; Carrat F; Gasparini R; Toniolo-Neto J; Drummond M; Weinstein M
    Value Health; 2007; 10(2):98-116. PubMed ID: 17391419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost effectiveness of a practice-based intervention to improve vaccination rates in adults less than 65-years-old.
    Smith KJ; Nowalk MP; Lin CJ; Zimmerman RK
    Hum Vaccin Immunother; 2017 Oct; 13(10):2207-2212. PubMed ID: 28829719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of adjuvanted versus nonadjuvanted influenza vaccine in adult hemodialysis patients.
    Lee BY; Stalter RM; Bacon KM; Tai JH; Bailey RR; Zimmer SM; Wagner MM
    Am J Kidney Dis; 2011 May; 57(5):724-32. PubMed ID: 21396760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
    Meier G; Gregg M; Poulsen Nautrup B
    J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
    Kim YK; Song JY; Jang H; Kim TH; Koo H; Varghese L; Han E
    Pharmacoeconomics; 2018 Dec; 36(12):1475-1490. PubMed ID: 30251078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults.
    Lee PY; Matchar DB; Clements DA; Huber J; Hamilton JD; Peterson ED
    Ann Intern Med; 2002 Aug; 137(4):225-31. PubMed ID: 12186512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany.
    Scholz SM; Weidemann F; Damm O; Ultsch B; Greiner W; Wichmann O
    Value Health; 2021 Jan; 24(1):32-40. PubMed ID: 33431151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of pneumococcal and influenza vaccination standing order programs.
    Lin CJ; Zimmerman RK; Smith KJ
    Am J Manag Care; 2013 Jan; 19(1):e30-7. PubMed ID: 23379777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effective, robust design of community mitigation for pandemic influenza: a systematic examination of proposed US guidance.
    Davey VJ; Glass RJ; Min HJ; Beyeler WE; Glass LM
    PLoS One; 2008 Jul; 3(7):e2606. PubMed ID: 18596963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A model-based economic analysis of pre-pandemic influenza vaccination cost-effectiveness.
    Halder N; Kelso JK; Milne GJ
    BMC Infect Dis; 2014 May; 14():266. PubMed ID: 24884470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. H5N1 Avian influenza: preventive and therapeutic strategies against a pandemic.
    Sambhara S; Poland GA
    Annu Rev Med; 2010; 61():187-98. PubMed ID: 20059335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) during an annual influenza epidemic and influenza pandemic in China.
    Caldwell R; Roberts CS; An Z; Chen CI; Wang B
    BMC Infect Dis; 2015 Jul; 15():284. PubMed ID: 26206275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
    Crépey P; Boiron L; Araujo RR; Lopez JG; Petitjean A; de Albuquerque Luna EJ
    BMC Public Health; 2020 Sep; 20(1):1374. PubMed ID: 32907562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preparing for pandemic influenza: should hospitals stockpile oseltamivir?
    Cinti S; Chenoweth C; Monto AS
    Infect Control Hosp Epidemiol; 2005 Nov; 26(11):852-4. PubMed ID: 16320980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.